Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Nektar Therapeutics (NKTR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,130,377
  • Shares Outstanding, K 174,307
  • Annual Sales, $ 1,193 M
  • Annual Income, $ 681,310 K
  • 60-Month Beta 2.82
  • Price/Sales 4.92
  • Price/Cash Flow 8.43
  • Price/Book 3.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.80
  • Number of Estimates 7
  • High Estimate -0.75
  • Low Estimate -0.86
  • Prior Year 5.33
  • Growth Rate Est. (year over year) -115.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.80 +14.19%
on 05/31/19
35.71 -1.51%
on 06/03/19
+3.15 (+9.84%)
since 05/17/19
3-Month
30.05 +17.04%
on 04/23/19
37.00 -4.95%
on 04/12/19
+0.24 (+0.69%)
since 03/18/19
52-Week
29.22 +20.36%
on 12/24/18
69.76 -49.58%
on 09/05/18
-23.24 (-39.79%)
since 06/18/18

Most Recent Stories

More News
Nektar (NKTR) Down 7% Since Last Earnings Report: Can It Rebound?

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NKTR : 35.17 (+4.36%)
Cancer-Fighting Stocks & ETF: What You Need to Know

Many biotech stocks soared after they presented very promising cancer treatment results at the ASCO conference

IOVA : 22.40 (+2.05%)
AZN : 40.95 (+2.43%)
CNCR : 20.97 (+1.99%)
MRK : 84.49 (+1.43%)
CHNA : 21.81 (+2.60%)
BMY : 47.79 (-0.87%)
NKTR : 35.17 (+4.36%)
Nektar (NKTR) in Focus: Stock Moves 8.8% Higher

Nektar (NKTR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

CPIX : 6.20 (+0.53%)
NKTR : 35.17 (+4.36%)
Amgen and PHV rise while Alphabet and Centene slip

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:

EE : 65.75 (+0.78%)
HUM : 257.96 (+1.25%)
PVH : 89.64 (+1.49%)
CY : 22.18 (+0.68%)
CNC : 55.26 (+0.45%)
AMGN : 181.61 (+1.81%)
NKTR : 35.17 (+4.36%)
Why Cancer-Fighting Stocks & ETFs Are Soaring

The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.

CELG : 97.15 (-0.15%)
IOVA : 22.40 (+2.05%)
AZN : 40.95 (+2.43%)
CNCR : 20.97 (+1.99%)
MRK : 84.49 (+1.43%)
CHNA : 21.81 (+2.60%)
LLY : 114.65 (+1.10%)
MRTX : 102.29 (+1.86%)
BMY : 47.79 (-0.87%)
NKTR : 35.17 (+4.36%)
Look for Shares of Nektar Therapeut to Potentially Pullback after Yesterday's 9.94% Rise

Nektar Therapeut (NASDAQ:NKTR) traded in a range yesterday that spanned from a low of $32.54 to a high of $35.71. Yesterday, the shares gained 9.9%, which took the trading range above the 3-day high...

NKTR : 35.17 (+4.36%)
Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary

Nektar (NKTR) forms wholly-owned subsidiary, Inheris Biopharm, focusing on CNS pipeline. The subsidiary will mainly be responsible for potential commercialization of under review pain drug, NKTR-181.

MRK : 84.49 (+1.43%)
LLY : 114.65 (+1.10%)
GILD : 68.20 (+1.64%)
NKTR : 35.17 (+4.36%)
Nektar Announces the Launch of Inheris Biopharma, Inc.

Nektar Therapeutics (Nasdaq: NKTR) today announced the formation of Inheris Biopharma, Inc., a wholly-owned subsidiary of Nektar and a CNS-focused company. Inheris will be responsible for launch preparation...

NKTR : 35.17 (+4.36%)
Shares of Nektar Therapeut Rank the Highest in Terms of Relative Performance in the Pharmaceuticals Industry (NKTR , LCI , ITCI , CTLT , JNJ )

Here are the top 5 stocks in the Pharmaceuticals industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

ITCI : 13.91 (-1.70%)
LCI : 5.44 (+2.64%)
NKTR : 35.17 (+4.36%)
Nektar Therapeut Set to Possibly Rebound After Yesterday's Selloff of 7.79%

Nektar Therapeut (NASDAQ:NKTR) traded in a range yesterday that spanned from a low of $31.15 to a high of $31.26. Yesterday, the shares fell 7.8%, which took the trading range below the 3-day low of...

NKTR : 35.17 (+4.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft. Long term indicators are in flux.

See More Share

Trade NKTR with:

Business Summary

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists...

See More

Key Turning Points

2nd Resistance Point 36.43
1st Resistance Point 35.80
Last Price 35.17
1st Support Level 34.17
2nd Support Level 33.17

See More

52-Week High 69.76
Fibonacci 61.8% 54.27
Fibonacci 50% 49.49
Fibonacci 38.2% 44.71
Last Price 35.17
52-Week Low 29.22

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar